Application of the complex Edelim in pathogenetic management of patients with erectile dysfunction
- Authors: Kyzlasov P.S.1, Volokitin E.V.2, Mustafayev A.T.1, Pomeshkin E.V.2
-
Affiliations:
- Medical and Biological University of Innovation and Continuing Education
- M.A. Podgorbunsky Kuzbass Сlinical Hospital of Emergency Medical Care
- Issue: Vol 11, No 3 (2021)
- Pages: 219-225
- Section: Original articles
- URL: https://journals.rcsi.science/uroved/article/view/74801
- DOI: https://doi.org/10.17816/uroved74801
- ID: 74801
Cite item
Abstract
AIM: To assess the degree of changes in complaints, dynamics of biochemical parameters of lipid metabolism, penile hemodynamics in patients with ED during therapy with EDELIM in comparison with PDE-5 inhibitors. Assess the tolerability of the drug based on the analysis of reported adverse events.
MATERIALS AND METHODS: The study was prospective comparative observational cohort. The study included 60 patients over 18 years old with complaints of persistent, at least 1 month, erectile dysfunction. The patients were divided into 2 groups: group 1 – patients with ED received Edelim on a regular basis, one capsule 2 times daily for 3 months; group 2 – patients with ED received generic tadalafil 5 mg daily for 1 month, then 1 month break, then 5 mg per day for 1 month.
RESULTS: The mean age of the patients was 38.4 ± 9.2 years. In group 1, significant differences were noted in the all hemodynamic and biochemical indicators, except for HDL levels (2.2 ± 0.4 vs. 2.3 ± 0.4 mmol/L; p = 0.067). In group 2, significant differences were noted in the dynamics of the IIEF-5 scale, the level of HDL, and the blood flow velocity in the right and left cavernous arteries. There were no significant differences in blood flow in the left and right dorsal arteries, levels of total cholesterol, LDL, triglycerides, glucose, HbA1c, systolic blood pressure. In the 1st group of patients, there were no adverse events, in the 2nd group, in 3 patients – mild side effects.
CONCLUSIONS: The improvement in the quality of erection in the group of patients taking Edelim is associated with decrease in the lipid profile, glucose, glycated hemoglobin, which can be regarded as a variant of pathogenetic conservative treatment of ED.
Full Text
##article.viewOnOriginalSite##About the authors
Pavel S. Kyzlasov
Medical and Biological University of Innovation and Continuing Education
Author for correspondence.
Email: dr.kyzlasov@mail.ru
ORCID iD: 0000-0003-1050-6198
SPIN-code: 6806-7913
Scopus Author ID: 57196124148
Dr. Sci. (Med.), Professor of Department Urology and Andrology
Russian Federation, 46, Zhivopisnaya str., Moscow, 123182Eugeniy V. Volokitin
M.A. Podgorbunsky Kuzbass Сlinical Hospital of Emergency Medical Care
Email: evgvolokitin82@mail.ru
ORCID iD: 0000-0003-1769-7759
Urologist
Russian Federation, KemerovoAli T. Mustafayev
Medical and Biological University of Innovation and Continuing Education
Email: dr.mustafayevat@gmail.com
ORCID iD: 0000-0002-2422-7942
SPIN-code: 5422-8789
Postgraduate student
Russian Federation, 46, Zhivopisnaya str., Moscow, 123182Evgeny V. Pomeshkin
M.A. Podgorbunsky Kuzbass Сlinical Hospital of Emergency Medical Care
Email: pomeshkin@mail.ru
ORCID iD: 0000-0002-5612-1878
SPIN-code: 5661-1947
Cand. Sci. (Med.), Head of the Urological Division
Russian Federation, KemerovoReferences
- Kaprin AD, Kostin AA, Kruglov DP, et al. Modern methods of instrumental diagnostics of vasculogenic erectile dysfunction. Experimental and Clinical Urology. 2016;(3):102–111. (In Russ.)
- Mironov SA, Artifeksov SB. Erectile dysfunction. Pathophysiology connection with adjustment disorder (review of the literature, short). Journal of New Medical Technologies. 2013;(1):171. (In Russ.) Avai¬lable from: https://cyberleninka.ru/article/n/erektilnaya-disfunktsiya-patofiziologicheskaya-svyaz-s-rasstroystvami-adaptatsii-obzor-literatury-kratkiy/viewer
- Bondarenko NA, Demyanova IO. Social protection of the population and its legal regulation in Russia. Uchenye zametki TOGU. 2017;(1–1):429–433. (In Russ.)
- Bondarenko VM, Dosta NI, Zhebentyaev AA. Some pathogenetic aspects of erectile dysfunction. Novosti khirurgii. 2015;23(2):217–225. (In Russ.) doi: 10.18484/2305-0047.2015.2.217
- Popov SV, Orlov IN, Grin’ YeA, et al. Erectile dysfunction: new technologies and approaches in diagnostics and treatment. Vestnik urologii. 2020;8(2):78–92. (In Russ.) doi: 10.21886/2308-6424-2020-8-2-78-92
- Mobley DF, Khera M, Baum N. Recent advances in the treatment of erectile dysfunction. Postgrad Med J. 2017;93(1105):679–685. doi: 10.1136/postgradmedj-2016-134073
- Imprialos KP, Stavropoulos K, Doumas M, et al. Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy. Curr Vasc Pharmacol. 2018;16(2):130–142. doi: 10.2174/1570161115666170609101502
- Chu NV, Edelman SV. Erectile dysfunction and diabetes. Curr Diab Rep. 2002;2(1):60–66. doi: 10.1007/s11892-002-0059-5
- Gamidov SI, Ovchinnikov RI, Popova AYu. Combined therapy of erectile dysfunction. Effektivnaya farmakoterapiya. 2017;(32):12–20. (In Russ.)
- Azimov SI, Gulamov MKh, Karimov BSU. Complex pathogenetic treatment of patients with diabetes mellitus complicated by erectile dysfunction. Vestnik Nauki i Obrazovaniya. 2020;(23(101)):76–80. (In Russ.)
- Andersson KE. Pharmacology of erectile function and dysfunction. Urol Clin North Am. 2001;28(2):233–247. doi: 10.1016/s0094-0143(05)70134-8
- Aita G, Ros CTD, Lorenzini F, et al. Erectile dysfunction: drug treatment. Rev Assoc Med Bras (1992). 2019;65(9):1133–1142. doi: 10.1590/1806-9282.65.9.1133
- Hsieh CH, Hsu GL, Chang SJ, et al. Surgical niche for the treatment of erectile dysfunction. Int J Urol. 2020;27(2):117–133. doi: 10.1111/iju.14157
- Munk NE, Knudsen JS, Comerma-Steffensen S, et al. Systematic Review of Oral Combination Therapy for Erectile Dysfunction When Phosphodiesterase Type 5 Inhibitor Monotherapy Fails. Sex Med Rev. 2019;7(3):430–441. doi: 10.1016/j.sxmr.2018.11.007
- Zhebentyaev AA, Goldytskii SO. Sovremennye metody diagnostiki i lecheniya erektil’noi disfunktsii. Surgery News. 2009;17(4): 150–159. (In Russ.)
- Kyzlasov PS, Bokov AI, Abdulkhamidov AN, et al. Novyi podkhod k revaskulyarizatsii polovogo chlena. In: Proceedings of the V congress of urologists of Siberia with international participation. Topical issues of urology; Krasnoyarsk, 13–14 May 2016. Krasnoyarsk: KASS; 2016. P. 152–154. (In Russ.)
- Burdin KA, Kyzlasov Pavel S, Mustafaev AT, et al. Justification of the optimal scheme of shock wave therapy for vasculogenic erectile dysfunction. Experimental and Clinical Urology. 2020;(4):89–95. (In Russ.) doi: 10.29188/2222-8543-2020-13-4-89-94
- Ivanov VA, Gunov SV. Anatomical aspects of disorder of venous blood outflow from cavity cells and method of its elimination. Integrativnye tendentsii v meditsine i obrazovanii. 2021;2:44–49. (In Russ.)
- Doppalapudi SK, Wajswol E, Shukla PA, et al. Endovascular Therapy for Vasculogenic Erectile Dysfunction: A Systematic Review and Meta-Analysis of Arterial and Venous Therapies. J Vasc Interv Radiol. 2019;30(8):1251–1258. doi: 10.1016/j.jvir.2019.01.024
- Kurbatov DG, Kuznetsky YuYa, Petritschko MI, et al. Conservative treatment of erectile dysfunction in men with age-related androgen deficiency. Vestnik Meditsinskogo stomatologicheskogo instituta. 2017;(2):24–31. (In Russ.)
- Bakr AM, El-Sakka AA, El-Sakka AI. Considerations for prescribing pharmacotherapy for the treatment of erectile dysfunction. Expert Opin Pharmacother. 2021;22(7):821–834. doi: 10.1080/14656566.2020.1851365